Su605 QUANTIFICATION OF INTESTINAL PERMEABILITY IN HUMAN CROHN'S DISEASE: A PRELUDE TO SPECIMEN-FREE, NON-INVASIVE ASSESSMENT OF HUMAN GUT BARRIER INTEGRITY USING PYRAZINE DERIVED FLUOROPHORES.

MLA

Holtz, Lori R., et al. “Su605 QUANTIFICATION OF INTESTINAL PERMEABILITY IN HUMAN CROHN’S DISEASE: A PRELUDE TO SPECIMEN-FREE, NON-INVASIVE ASSESSMENT OF HUMAN GUT BARRIER INTEGRITY USING PYRAZINE DERIVED FLUOROPHORES.” Gastroenterology (00165085), vol. 160, no. 6, May 2021, p. S-753. EBSCOhost, https://doi.org/10.1016/S0016-5085(21)02511-7.

APA

Holtz, L. R., Nix, B. D., Akuse, S. E., Hall-Moore, C., Newberry, R. D., Ciorba, M. A., Deepak, P., Shieh, J. J., Johnson, J. R., Riley, I. R., & Dorshow, R. (2021). Su605 QUANTIFICATION OF INTESTINAL PERMEABILITY IN HUMAN CROHN’S DISEASE: A PRELUDE TO SPECIMEN-FREE, NON-INVASIVE ASSESSMENT OF HUMAN GUT BARRIER INTEGRITY USING PYRAZINE DERIVED FLUOROPHORES. Gastroenterology (00165085), 160(6), S-753. https://doi.org/10.1016/S0016-5085(21)02511-7

Chicago

Holtz, Lori R., Billy D. Nix, Sewuese E. Akuse, Carla Hall-Moore, Rodney D. Newberry, Matthew A. Ciorba, Parakkal Deepak, et al. 2021. “Su605 QUANTIFICATION OF INTESTINAL PERMEABILITY IN HUMAN CROHN’S DISEASE: A PRELUDE TO SPECIMEN-FREE, NON-INVASIVE ASSESSMENT OF HUMAN GUT BARRIER INTEGRITY USING PYRAZINE DERIVED FLUOROPHORES.” Gastroenterology (00165085) 160 (6): S-753. doi:10.1016/S0016-5085(21)02511-7.